WASHINGTON – October 28, 2026 -- LUNGevity Foundation and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) have awarded $620,000 to an early-phase clinical trial at The Ohio State University Comprehensive Cancer Center. The trial will test whether pairing two FDA-approved drugs can stop resistance to osimertinib in EGFR-positive non-small cell lung cancer (NSCLC).